Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is -7.35% lower on its value in year-to-date trading and has touched a low of $3.30 and a high of $7.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VNDA stock was last observed hovering at around $3.80 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $3.91, the stock is -4.79% and -1.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.71 million and changing 2.89% at the moment leaves the stock -17.43% off its SMA200. VNDA registered -41.73% loss for a year compared to 6-month gain of -8.64%. The firm has a 50-day simple moving average (SMA 50) of -$0.80 and a 200-day simple moving average (SMA200) of $14.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.91% loss in the last 1 month and extending the period to 3 months gives it a -1.76%, and is 2.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.54% over the week and 4.13% over the month.
Vanda Pharmaceuticals Inc (VNDA) has around 203 employees, a market worth around $224.98M and $192.64M in sales. Current P/E ratio is 89.47. Profit margin for the company is 1.30%. Distance from 52-week low is 18.66% and -44.14% from its 52-week high. The company has generated returns on investments over the last 12 months (0.45%).
Vanda Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at $0.05 with sales reaching $48.5M over the same period.The EPS is expected to shrink by -75.00% this year, but quarterly earnings will post -2.40% year-over-year.
214 institutions hold shares in Vanda Pharmaceuticals Inc (VNDA), with institutional investors hold 97.37% of the company’s shares. The shares outstanding are 57.53M, and float is at 54.51M with Short Float at 5.95%. Institutions hold 92.19% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 10.81 million shares valued at $71.24 million. The investor’s holdings represent 18.80% of the VNDA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 4.24 million shares valued at $27.92 million to account for 7.37% of the shares outstanding. The other top investors are State Street Corporation which holds 4.08 million shares representing 7.10% and valued at over $26.89 million, while Renaissance Technologies, LLC holds 5.41% of the shares totaling 3.11 million with a market value of $20.51 million.
Vanda Pharmaceuticals Inc (VNDA) Insider Activity
The most recent transaction is an insider sale by Polymeropoulos Mihael Hristos, the company’s President and CEO. SEC filings show that Polymeropoulos Mihael Hristos sold 24,288 shares of the company’s common stock on Mar 05 ’24 at a price of $4.13 per share for a total of $0.1 million. Following the sale, the insider now owns 1.87 million shares.
Vanda Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 05 ’24 that Wijkstrom Joakim (SVP, Chief Marketing Officer) sold a total of 9,229 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $4.21 per share for $38830.0. Following the transaction, the insider now directly holds 0.13 million shares of the VNDA stock.
Still, SEC filings show that on Mar 05 ’24, Moran Kevin Patrick (SVP, CFO & Treasurer) disposed off 8,902 shares at an average price of $4.20 for $37411.0. The insider now directly holds 231,014 shares of Vanda Pharmaceuticals Inc (VNDA).
